Mutation hotspots in the p53 gene in tumors of different origin: Correlation with evolutionary conservation and signs of positive selection

Biochimica et Biophysica Acta - Gene Structure and Expression

Volumn 1679, Issue 2, 2004, Pages 95-106

  Glazko, Galina V ^a,b   Koonin, Eugene V ^c   Rogozin, Igor B ^b,c  

^a STOWERS INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Cancer; Classification; Comparative analysis; Hotspot; p53 gene; p63 73 family members

Indexed keywords

PROTEIN P53; PROTEIN P63;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER CELL; CARCINOGENESIS; CELL GROWTH; CORRELATION ANALYSIS; DNA BINDING; FAMILIAL CANCER; GENE CONSTRUCT; GENE MAPPING; GENE MUTATION; LUNG CANCER; LYMPHOMA; PRIORITY JOURNAL; PURIFICATION; SOLID TUMOR;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; BASE SEQUENCE; BINDING SITES; CPG ISLANDS; DNA-BINDING PROTEINS; EVOLUTION, MOLECULAR; GENES, P53; GENES, TUMOR SUPPRESSOR; GERM-LINE MUTATION; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASMS; NUCLEAR PROTEINS; PHOSPHOPROTEINS; PHYLOGENY; SELECTION (GENETICS); SEQUENCE ALIGNMENT; STATISTICS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 3543059328     PISSN: 01674781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbaexp.2004.05.004     Document Type: Article

References (81)

1. Hansen R., Oren M. p53; from inductive signal to cellular effect. Curr. Opin. Genet. Dev. 7:1997;46-51
2. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331
3. Agarwal M.L., Taylor W.R., Chernov M.V., Chernova O.B., Stark G.R. The p53 network. J. Biol. Chem. 273:1998;1-4
4. Guimaraes D.P., Hainaut P. TP53: a key gene in human cancer. Biochimie. 84:2002;83-93
5. Giaccia A.J., Kastan M.B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12:1998;2973-2983
6. Linke S.P., Clarkin K.C., Wahl G.M. p53 mediates permanent arrest over multiple cell cycles in response to gamma-irradiation. Cancer Res. 57:1997;1171-1179
7. Pluquet O., Hainaut P. Genotoxic and non-genotoxic pathways of p53 induction. Cancer Lett. 174:2001;1-15
8. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70
9. Lane D.P., Benchimol S. p53: oncogene or anti-oncogene? Genes Dev. 4:1990;1-8
10. Blagosklonny M.V. p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect. FASEB J. 14:2000;1901-1907
11. Resnick M.A., Inga A. Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc. Natl. Acad. Sci. U. S. A. 100:2003;9934-9939
12. Pugacheva E.N., Ivanov A.V., Kravchenko J.E., Kopnin B.P., Levine A.J., Chumakov P.M. Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Oncogene. 21:2002;4595-4600
13. Parant J.M., Lozano G. Disrupting TP53 in mouse models of human cancers. Hum. Mutat. 21:2003;321-326
14. Donehower L.A. The p53-deficient mouse: a model for basic and applied cancer studies. Semin. Cancer. Biol. 7:1996;269-278
15. Komarova E.A., Chernov M.V., Franks R., Wang K., Armin G., Zelnick C.R., Chin D.M., Bacus S.S., Stark G.R., Gudkov A.V. Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J. 16:1997;1391-1400
16. Drake J.W., Baltz R.H. The biochemistry of mutagenesis. Annu. Rev. Biochem. 45:1976;11-37
17. Lindahl T. Instability and decay of the primary structure of DNA. Nature. 362:1993;709-715
18. Horsfall M.J., Gordon A.J., Burns P.A., Zielenska M., van der Vliet G.M., Glickman B.W. Mutational specificity of alkylating agents and the influence of DNA repair. Environ. Mol. Mutagen. 15:1990;107-122
19. Dogliotti E., Hainaut P., Hernandez T., D'Errico M., DeMarini D.M. Mutation spectra resulting from carcinogenic exposure: from model systems to cancer-related genes. Recent Results Cancer Res. 154:1998;97-124
20. Maki H. Origins of spontaneous mutations: specificity and directionality of base-substitution, frameshift, and sequence-substitution mutageneses. Annu. Rev. Genet. 36:2002;279-303
21. Rogozin I.B., Pavlov Y.I. Theoretical analysis of mutation hotspots and their DNA sequence context specificity. Mutat. Res. 544:2003;65-85
22. Hussain S.P., Harris C.C. p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutat. Res. 428:1999;23-32
23. Soussi T., Dehouche K., Beroud C. p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum. Mutat. 15:2000;105-113
24. Krawczak M., Smith-Sorensen B., Schmidtke J., Kakkar V.V., Cooper D.N., Hovig E. Somatic spectrum of cancer-associated single basepair substitutions in the TP53 gene is determined mainly by endogenous mechanisms of mutation and by selection. Hum. Mutat. 5:1995;48-57
25. Walker D.R., Bond J.P., Tarone R.E., Harris C.C., Makalowski W., Boguski M.S., Greenblatt M.S. Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features. Oncogene. 18:1999;211-218
26. Hollstein M., Hergenhahn M., Yang Q., Bartsch H., Wang Z.Q., Hainaut P. New approaches to understanding p53 gene tumor mutation spectra. Mutat. Res. 431:1999;199-209
27. Greenblatt M.S., Beaudet J.G., Gump J.R., Godin K.S., Trombley L., Koh J., Bond J.P. Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants. Oncogene. 22:2003;1150-1163
28. Cooper D.N., Youssoufian H. The CpG dinucleotide and human genetic disease. Hum. Genet. 78:1988;151-155
29. Beroud C., Soussi T. p53 gene mutation: software and database. Nucleic Acids Res. 26:1998;200-204
30. Hainaut P., Hernandez T., Robinson A., Rodriguez-Tome P., Flores T., Hollstein M., Harris C.C., Montesano R. IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res. 26:1998;205-213
31. Soussi T., Beroud C. Significance of TP53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides. Hum. Mutat. 21:2003;192-200
32. Lutz W.K., Fekete T., Vamvakas S. Position-and base pair-specific comparison of p53 mutation spectra in human tumors: elucidation of relationships between organs for cancer etiology. Environ. Health Perspect. 106:1998;207-211
33. Glazko G.V., Rogozin I.B., Sozinov A.A. The mutational spectra of gene p53 in different types of tumors. Tsitol. Genet. 33:1999;14-20
34. Yamamoto S., Romanenko A., Wei M., Masuda C., Zaparin W., Vinnichenko W., Vozianov A., Lee C.C., Morimura K., Wanibuchi H., Tada M., Fukushima S. Specific p53 gene mutations in urinary bladder epithelium after the Chernobyl accident. Cancer Res. 59:1999;3606-3609
35. Varley J.M. Germline TP53 mutations and Li-Fraumeni syndrome. Hum. Mutat. 21:2003;313-320
36. Glazko G.V., Milanesi L., Rogozin I.B. The subclass approach for mutational spectrum analysis: application of the SEM algorithm. J. Theor. Biol. 192:1998;475-487
37. Rogozin I.B., Kondrashov F.A., Glazko G.V. Use of mutation spectra analysis software. Hum. Mutat. 17:2001;83-102
38. Kleihues P., Schauble B., zur Hausen A., Esteve J., Ohgaki H. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am. J. Pathol. 150:1997;1-13
39. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 19:2002;607-614
40. Sedlacek Z., Kodet R., Poustka A., Goetz P. A database of germline p53 mutations in cancer-prone families. Nucleic Acids Res. 26:1998;214-215
41. Beroud C., Soussi T. The UMD-p53 database: new mutations and analysis tools. Hum. Mutat. 21:2003;176-181
42. Adams W.T., Skopek T.R. Statistical test for the comparison of samples from mutational spectra. J. Mol. Biol. 194:1987;391-396
43. Cariello N.F., Piegorsch W.W., Adams W.T., Skopek T.R. Computer program for the analysis of mutational spectra: application to p53 mutations. Carcinogenesis. 15:1994;2281-2285
44. Piegorsch W.W., Bailer A.J. Statistical approaches for analyzing mutational spectra: some recommendations for categorical data. Genetics. 136:1994;403-416
45. Khromov-Borisov N.N., Rogozin I.B., Pegas Henriques J.A., de Serres F.J. Similarity pattern analysis in mutational distributions. Mutat. Res. 430:1999;55-74
46. Thompson J.D., Gibson T.J., Plewniak F., Jeanmougin F., Higgins D.G. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 25:1997;4876-4882
47. Nei M., Kumar S. Molecular Evolution and Phylogenetics. 2001;Oxford Univ., Oxford
48. Yang Z. PAML: a program package for phylogenetic analysis by maximum likelihood. Comput. Appl. Biosci. 13:1997;555-556
49. Zhang J., Rosenberg H.F., Nei M. Positive Darwinian selection after gene duplication in primate ribonuclease genes. Proc. Natl. Acad. Sci. U. S. A. 95:1998;3708-3713
50. Wacey A.I., Cooper D.N., Liney D., Hovig E., Krawczak M. Disentangling the perturbational effects of amino acid substitutions in the DNA-binding domain of p53. Hum. Genet. 104:1999;15-22
51. Hurst L.D. The Ka/Ks ratio: diagnosing the form of sequence evolution. Trends Genet. 18:2002;486
52. Benzer S. On the topography of the genetic fine structure. Proc. Natl. Acad. Sci. U. S. A. 47:1961;403-415
53. Streisinger G., Okada Y., Emrich J., Newton J., Tsugita A., Terzaghi E., Inouye M. Frameshift mutations and the genetic code. Cold Spring Harbor Symp. Quant. Biol. 31:1966;77-84
54. Neuberger M.S., Milstein C. Somatic hypermutation. Curr. Opin. Immunol. 7:1995;248-254
55. Zavolan M., Kepler T.B. Statistical inference of sequence-dependent mutation rates. Curr. Opin. Genet. Dev. 11:2001;612-615
56. Topal M.D., Eadie J.S., Conrad M. O6-methylguanine mutation and repair is nonuniform. Selection for DNA most interactive with O6-methylguanine. J. Biol. Chem. 261:1986;9879-9885
57. Fijal B.A., Idury R.M., Witte J.S. Analysis of mutational spectra: locating hotspots and clusters of mutations using recursive segmentation. Stat. Med. 21:2002;1867-1885
58. Nicolson G.L. Tumor cell instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res. 47:1987;1473-1487
59. Dulbecco R. Cancer progression: the ultimate challenge. Int. J. Cancer. (Suppl. 4):1989;6-9
60. Rubin A.L., Yao A., Rubin H. Relation of spontaneous transformation in cell culture to adaptive growth and clonal heterogeneity. Proc. Natl. Acad. Sci. U. S. A. 87:1990;482-486
61. Hainaut P., Pfeifer G.P. Patterns of p53 G→T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis. 22:2001;367-374
62. Denissenko M.F., Pao A., Tang M., Pfeifer G.P. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science. 274:1996;430-432
63. Vahakangas K.H., Bennett W.P., Castren K., Welsh J.A., Khan M.A., Blomeke B., Alavanja M.C., Harris C.C. p53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Res. 61:2001;4350-4356
64. Pfeifer G.P., Denissenko M.F., Olivier M., Tretyakova N., Hecht S.S., Hainaut P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene. 21:2002;7435-7451
65. Rodin S.N., Rodin A.S. On the origin of p53 G:C→T:A transversions in lung cancers. Mutat. Res. 508:2002;1-19
66. Walker K.K., Levine A.J. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc. Natl. Acad. Sci. U. S. A. 93:1996;15335-15340
67. Chang J., Kim D.H., Lee S.W., Choi K.Y., Sung Y.C. Transactivation ability of p53 transcriptional activation domain is directly related to the binding affinity to TATA-binding protein. J. Biol. Chem. 270:1995;25014-25019
68. Murphy M., Hinman A., Levine A.J. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev. 10:1996;2971-2980
69. Zhu J., Zhou W., Jiang J., Chen X. Identification of a novel p53 functional domain that is necessary for mediating apoptosis. J. Biol. Chem. 273:1998;13030-13036
70. Arrowsmith C.H. Structure and function in the p53 family. Cell Death Differ. 6:1999;1169-1173
71. Courtois S., de Fromentel C.C., Hainaut P. p53 protein variants: structural and functional similarities with p63 and p73 isoforms. Oncogene. 23:2004;631-638
72. Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 265:1994;346-355
73. Mihara M., Erster S., Zaika A., Petrenko O., Chittenden T., Pancoska P., Moll U.M. p53 has a direct apoptogenic role at the mitochondria. Mol. Cell. 11:2003;577-590
74. Moll U.M., Erster S., Zaika A. p53, p63 and p73-solos, alliances and feuds among family members. Biochim. Biophys. Acta. 1552:2001;47-59
75. Benard J., Douc-Rasy S., Ahomadegbe J.C. TP53 family members and human cancers. Hum. Mutat. 21:2003;182-191
76. Schmale H., Bamberger C. A novel protein with strong homology to the tumor suppressor p53. Oncogene. 15:1997;1363-1367
77. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.C., Valent A., Minty A., Chalon P., Lelias J.M., Dumont X., Ferrara P., McKeon F., Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 90:1997;809-819
78. Marin M.C., Kaelin W.G. Jr. p63 and p73: old members of a new family. Biochim. Biophys. Acta. 1470:2000);M93-M100
79. Lohrum M.A., Vousden K.H. Regulation and function of the p53-related proteins: same family, different rules. Trends Cell. Biol. 10:2000;197-202
80. Strano S., Rossi M., Fontemaggi G., Munarriz E., Soddu S., Sacchi A., Blandino G. From p63 to p53 across p73. FEBS Lett. 490:2001;163-170
81. Miller M.P., Kumar S. Understanding human disease mutations through the use of interspecific genetic variation. Hum. Mol. Genet. 10:2001;2319-2328